These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 9145816)
1. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones. Wise R; Brenwald NP; Andrews JM; Boswell F J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816 [TBL] [Abstract][Full Text] [Related]
2. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. Pontani D; Washton H; Bouchillon S; Johnson J Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284 [TBL] [Abstract][Full Text] [Related]
3. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. Hoogkamp-Korstanje JA J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498 [TBL] [Abstract][Full Text] [Related]
4. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. Wise R; Andrews JM; Brenwald N J Antimicrob Chemother; 1993 Apr; 31(4):497-504. PubMed ID: 8390433 [TBL] [Abstract][Full Text] [Related]
5. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone. Wise R; Andrews JM; Brenwald N J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of BAY 12-8039, a new fluoroquinolone. Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763 [TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. Fung-Tomc J; Minassian B; Kolek B; Washo T; Huczko E; Bonner D J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819 [TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of four new fluoroquinolones. García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215 [TBL] [Abstract][Full Text] [Related]
9. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Child J; Andrews J; Boswell F; Brenwald N; Wise R J Antimicrob Chemother; 1995 Jun; 35(6):869-76. PubMed ID: 7559198 [TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. Cooper MA; Andrews JM; Ashby JP; Matthews RS; Wise R J Antimicrob Chemother; 1990 Nov; 26(5):667-76. PubMed ID: 2079449 [TBL] [Abstract][Full Text] [Related]
11. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates. Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates. Ling TK; Liu EY; Cheng AF Chemotherapy; 1999; 45(1):22-7. PubMed ID: 9876206 [TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of WIN 57273 compared to the activity of other fluoroquinolones and two beta-lactam antibiotics. Chin NX; Neu HC J Antimicrob Chemother; 1991 Jun; 27(6):781-91. PubMed ID: 1657856 [TBL] [Abstract][Full Text] [Related]
16. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. Bauernfeind A J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. Bauernfeind A J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311 [TBL] [Abstract][Full Text] [Related]